| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
URAT1 (uric acid transporter 1). This compound specifically targets the URAT1 protein, which is responsible for the reabsorption of uric acid from the renal tubular lumen back into the bloodstream. By inhibiting URAT1, the compound reduces uric acid reabsorption and promotes its excretion in urine.
|
|---|---|
| ln Vitro |
URAT1 inhibitor 1 demonstrates potent in vitro activity with an IC50 of 32 nM against URAT1. This high potency indicates strong binding affinity and effective inhibition of the transporter at nanomolar concentrations. The compound's in vitro efficacy is measured by its ability to inhibit urate transport in URAT1-expressing cell models.
|
| ln Vivo |
In vivo, URAT1 inhibitor 1 is expected to lower serum urate levels by promoting renal uric acid excretion. While specific in vivo data for this compound are limited, URAT1 inhibitors as a class have demonstrated efficacy in reducing serum urate in animal models of hyperuricemia. The compound shows potential for the study of hyperuricemic gout.
|
| Enzyme Assay |
The typical assay for URAT1 inhibitors involves measuring the uptake of radiolabeled uric acid (e.g., 14C-uric acid) into cells overexpressing human URAT1. Test compound is added at various concentrations to determine the IC50 for inhibition of urate uptake. Cells are incubated with the compound and substrate for a specified period, followed by washing and scintillation counting to quantify remaining intracellular radiolabel.
|
| Cell Assay |
URAT1-overexpressing cell lines (e.g., HEK293 or CHO cells stably expressing human URAT1) are seeded in multi-well plates. Cells are pre-incubated with serial dilutions of the test compound for a short period, then 14C-uric acid is added. After incubation, cells are washed with ice-cold buffer to stop uptake, lysed, and the radioactivity is measured. IC50 values are calculated from dose-response curves.
|
| Animal Protocol |
C57BL/6 mice or rats are administered a high-purine diet or potassium oxonate (a uricase inhibitor) to induce hyperuricemia. The test compound is administered orally or intravenously. Blood samples are collected at various time points to measure serum urate levels. Urine is also collected to quantify uric acid excretion. Efficacy is determined by the reduction in serum urate compared to vehicle control.
|
| ADME/Pharmacokinetics |
As a small molecule URAT1 inhibitor, the compound is expected to have oral bioavailability. The molecular weight is 569.29 g/mol and the formula is C1₉H1₅Br2N₅O2S2. PK parameters such as half-life, Cmax, and AUC would be determined in standard rodent PK studies following oral and intravenous administration. The compound is typically formulated in suitable vehicles for in vivo administration.
|
| Toxicity/Toxicokinetics |
Toxicology data for URAT1 inhibitor 1 are not publicly available. As a preclinical research compound, standard toxicity screening would include cytotoxicity assays in mammalian cell lines, hERG channel inhibition testing for cardiac safety, and preliminary rodent toxicology studies to determine maximum tolerated dose and identify potential target organs of toxicity.
|
| References | |
| Additional Infomation |
URAT1 inhibitor 1 is a research-use chemical probe for studying urate transport and hyperuricemia. It has not entered clinical trials and is not FDA-approved. The compound is structurally characterized by a complex heterocyclic core with bromine substituents. As a URAT1 inhibitor, it belongs to a class of drugs being developed for gout treatment, with lesinurad being an example of an approved URAT1 inhibitor.
|
| Molecular Formula |
C19H15BR2N5O2S2
|
|---|---|
| Molecular Weight |
569.29
|
| Exact Mass |
568.901
|
| CAS # |
2268720-62-1
|
| PubChem CID |
138454759
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
668
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C=C(C2C(=CC=CC=2)C=1Br)CN1C(SCS(=O)(=O)NC2C=CC=NC=2)=NN=C1Br
|
| InChi Key |
KPBJDNPRRPXSOG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H15Br2N5O2S2/c20-17-8-7-13(15-5-1-2-6-16(15)17)11-26-18(21)23-24-19(26)29-12-30(27,28)25-14-4-3-9-22-10-14/h1-10,25H,11-12H2
|
| Chemical Name |
1-[[5-bromo-4-[(4-bromonaphthalen-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]-N-pyridin-3-ylmethanesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~219.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7566 mL | 8.7829 mL | 17.5657 mL | |
| 5 mM | 0.3513 mL | 1.7566 mL | 3.5131 mL | |
| 10 mM | 0.1757 mL | 0.8783 mL | 1.7566 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
